Selective Modulation of the Androgen Receptor Activation Function-2 Domain Rescues Degeneration in Spinal Bulbar Muscular Atrophy

Spinal bulbar muscular atrophy (SBMA) is a motor neuron disease caused by toxic gain of function of the androgen receptor (AR). Previously, we found that co-regulator binding through the activation function-2 (AF2) domain of AR is essential for pathogenesis, suggesting that AF2 may be a potential drug target for selective modulation of toxic AR activity. We screened previously identified AF2 modulators for their ability to rescue toxicity in a Drosophila model of SBMA. We identified two compounds, tolfenamic acid (TA) and 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole (MEPB), as top candidates for rescuing lethality, locomotor function and neuromuscular junction defects in SBMA flies. Pharmacokinetic analyses in mice revealed a more favorable bioavailability and tissue retention of MEPB compared with TA in muscle, brain and spinal cord. In a preclinical trial in a new mouse model of SBMA, MEPB treatment yielded a dose-dependent rescue from loss of body weight, rotarod activity and grip strength. In addition, MEPB ameliorated neuronal loss, neurogenic atrophy and testicular atrophy, validating AF2 modulation as a potent androgen-sparing strategy for SBMA therapy.

[1]  Myles A Brown,et al.  Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-binding Motif* , 2014, The Journal of Biological Chemistry.

[2]  S. Tsuji,et al.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[3]  G. Cioni,et al.  Immunohistochemical study of muscle biopsy in children with cerebral palsy , 2002, Brain and Development.

[4]  J. Finsterer.  Perspectives of Kennedy's disease , 2010, Journal of the Neurological Sciences.

[5]  K. Fischbeck,et al.  A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. , 2016, Human molecular genetics.

[6]  S. B. Pedersen.  Biopharmaceutical aspects of tolfenamic acid. , 1994, Pharmacology & toxicology.

[7]  J. Sanes,et al.  Neural cell adhesion molecule in normal, denervated, and myopathic human muscle , 1987, Annals of neurology.

[8]  G. Sobue,et al.  ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor , 2007, Nature Medicine.

[9]  Rebecca B. Smith,et al.  Native Functions of the Androgen Receptor Are Essential to Pathogenesis in a Drosophila Model of Spinobulbar Muscular Atrophy , 2010, Neuron.

[10]  F. Shann,et al.  A multicentre, randomised, double-blind, placebo-controlled trial of aminophylline for bronchiolitis in infants admitted to intensive care. , 2014, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[11]  A. Zoubeidi,et al.  Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. , 2014, Chemistry & biology.

[12]  G. Coetzee,et al.  Structural and functional consequences of glutamine tract variation in the androgen receptor. , 2004, Human molecular genetics.

[13]  E. Wilson,et al.  Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone* , 2007, Journal of Biological Chemistry.

[14]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[15]  L. Greensmith,et al.  Correlation of clinical and molecular features in spinal bulbar muscular atrophy , 2022 .

[16]  O. Bonnevie,et al.  A comparative study of the influence of tolfenamic acid (Clotam) and diclofenac sodium (Voltaren) on the gastrointestinal mucosa in patients with a history of NSAID-related dyspeptic symptoms. , 1994, Pharmacology & toxicology.

[17]  D. Robins,et al.  Androgen receptor variants and prostate cancer in humanized AR mice , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  Artem Cherkasov,et al.  Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives. , 2013, Journal of medicinal chemistry.

[19]  J. Hendel.  The overall safety of tolfenamic acid. , 1994, Pharmacology & toxicology.

[20]  J. M. Barrett,et al.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells , 2011, Molecular and Cellular Endocrinology.

[21]  J. Mandrekar,et al.  Natural history of spinal-bulbar muscular atrophy , 2008, Neurology.

[22]  Stephanie Daignault,et al.  Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice. , 2008, Human molecular genetics.

[23]  G. Sobue,et al.  Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy , 2009, Annals of neurology.

[24]  L. Martini,et al.  Reflections on the diseases linked to mutations of the androgen receptor , 2005, Endocrine.

[25]  R. Albin,et al.  Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. , 2006, The American journal of pathology.

[26]  Huiqing Yuan,et al.  Suppression of the androgen receptor function by quercetin through protein–protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells , 2010, Molecular and Cellular Biochemistry.

[27]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  Artem Cherkasov,et al.  Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening. , 2011, Journal of medicinal chemistry.

[29]  P. Cozzone,et al.  Spinal cord blood flow measurement by arterial spin labeling , 2008, Magnetic resonance in medicine.

[30]  G. Moretto,et al.  Spinal and bulbar muscular atrophy: Skeletal muscle pathology in male patients and heterozygous females , 2008, Journal of the Neurological Sciences.

[31]  J. Kopchick,et al.  Differential inhibition of postnatal brain, spinal cord and body growth by a growth hormone antagonist , 2004, BMC Neuroscience.

[32]  P. Rennie,et al.  Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3). , 2014, Journal of medicinal chemistry.

[33]  Howard C. Shen,et al.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor , 2008, Molecular Cancer Therapeutics.

[34]  M. W. Glynn,et al.  Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. , 2005, Human molecular genetics.

[35]  M Alter,et al.  Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. , 1968, Neurology.

[36]  M. Gibaldi,et al.  Pharmacokinetics, Second Edition , 1982 .

[37]  L. Sweeney,et al.  Physiologically based pharmacokinetic modeling of chloroethane disposition in mice, rats, and women. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  K. Fischbeck,et al.  Characterization of an Expanded Glutamine Repeat Androgen Receptor in a Neuronal Cell Culture System , 1997, Neurobiology of Disease.

[39]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[40]  M. Pellegrini,et al.  Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet , 2016, Acta Neuropathologica.

[41]  G. Sobue,et al.  Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy , 2003, Nature Medicine.

[42]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[43]  T. Corell.  Pharmacology of tolfenamic acid. , 1994, Pharmacology & toxicology.

[44]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[45]  勝野 雅央.  Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy , 2003 .

[46]  G. Stoltenburg‐Didinger,et al.  Expression of Leu‐19 (CD56, N‐CAM) and nitric oxide synthase (NOS) I in denervated and reinnervated human skeletal muscle , 2001, Microscopy research and technique.

[47]  Artem Cherkasov,et al.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. , 2011, Journal of medicinal chemistry.

[48]  Sang-Ah Lee,et al.  Association between CAG repeat polymorphisms and the risk of prostate cancer: a meta-analysis by race, study design and the number of (CAG)n repeat polymorphisms. , 2013, International journal of molecular medicine.

[49]  Huiyi Wang,et al.  Castration Restores Function and Neurofilament Alterations of Aged Symptomatic Males in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy , 2004, The Journal of Neuroscience.

[50]  D. Pressman,et al.  Plasma and Blood Volumes of Mouse Organs, As Determined with Radioactive Iodoproteins.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[51]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.